REGENXBIO Inc. (RGNX) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
RGNX Revenue Growth
Revenue Breakdown (FY 2024)
RGNX's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
RGNX Revenue Analysis (2013–2024)
As of May 8, 2026, REGENXBIO Inc. (RGNX) generated trailing twelve-month (TTM) revenue of $161.3 million, reflecting exceptional growth of +22.9% year-over-year. The most recent quarter (Q3 2025) recorded $29.7 million in revenue, up 39.2% sequentially.
Looking at the longer-term picture, RGNX's 5-year compound annual growth rate (CAGR) stands at +18.8%, indicating consistent double-digit revenue growth. The company achieved its highest annual revenue of $470.3 million in 2021.
Revenue diversification analysis shows RGNX's business is primarily driven by License and Service (100%). With over half of revenue concentrated in License and Service, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including SGMO (-37.1% YoY), KRYS (+25.1% YoY), and SRPT (-2.2% YoY), RGNX has underperformed the peer group in terms of revenue growth. Compare RGNX vs SGMO →
RGNX Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| RGNXCurrent | $161M | +22.9% | +18.8% | -280.0% | |
 SGMO | $58M | -37.1% | -10.8% | -179.9% | |
 KRYS | $389M | +25.1% | - | 41.5% | |
 SRPT | $2.2B | -2.2% | +32.4% | -29.9% | |
 RARE | $673M | +13.3% | +19.9% | -79.5% |
RGNX Historical Revenue Data (2013–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $83.3M | -7.7% | $49.8M | 59.7% | $-233,346,000 | -280.0% |
| 2023 | $90.2M | -19.9% | $53.0M | 58.8% | $-268,128,000 | -297.1% |
| 2022 | $112.7M | -76.0% | $58.2M | 51.6% | $-262,876,000 | -233.2% |
| 2021 | $470.3M | +204.3% | $418.5M | 89.0% | $160.0M | 34.0% |
| 2020 | $154.6M | +338.7% | $118.9M | 76.9% | $-119,233,000 | -77.1% |
| 2019 | $35.2M | -83.9% | $27.0M | 76.6% | $-148,998,000 | -422.9% |
| 2018 | $218.5M | +2002.4% | $208.9M | 95.6% | $88.1M | 40.3% |
| 2017 | $10.4M | +126.5% | $8.7M | 83.6% | $-75,885,000 | -730.2% |
| 2016 | $4.6M | -39.5% | $3.6M | 79.1% | $-65,340,000 | -1423.8% |
| 2015 | $7.6M | +24.0% | $6.1M | 80.2% | $-23,137,000 | -304.9% |
See RGNX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs RGNX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare RGNX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonRGNX — Frequently Asked Questions
Quick answers to the most common questions about buying RGNX stock.
Is RGNX's revenue growth accelerating or slowing?
RGNX revenue is accelerating at +22.9% year-over-year, exceeding the 5-year CAGR of +18.8%. TTM revenue reached $161M. Growth momentum has increased versus prior periods.
What is RGNX's long-term revenue growth rate?
REGENXBIO Inc.'s 5-year revenue CAGR of +18.8% reflects the sustained expansion pattern. Current YoY growth of +22.9% is above this long-term average.
How is RGNX's revenue distributed by segment?
RGNX reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.